SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]
SEC Accession No. 0001640334-22-002477
Filing Date
2022-11-16
Accepted
2022-11-16 10:37:40
Documents
46
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 6-KA nymox_6ka.htm   iXBRL 6-K/A 48244
2 QUARTERLY REPORT nymox_ex991.htm   iXBRL EX-99.1 499189
3 CEO CERTIFICATION nymox_ex992.htm EX-99.2 17111
4 CFO CERTIFICATION nymox_ex993.htm EX-99.3 16588
  Complete submission text file 0001640334-22-002477.txt   2349026

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA nymox-20220930.xsd EX-101.SCH 39156
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE nymox-20220930_lab.xml EX-101.LAB 155614
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nymox-20220930_cal.xml EX-101.CAL 32314
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nymox-20220930_pre.xml EX-101.PRE 126008
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nymox-20220930_def.xml EX-101.DEF 61691
40 EXTRACTED XBRL INSTANCE DOCUMENT nymox_6ka_htm.xml XML 368764
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K/A | Act: 34 | File No.: 001-12033 | Film No.: 221393666
SIC: 2835 In Vitro & In Vivo Diagnostic Substances